AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CONSONANCE
- Sponsors Roche
- 19 Nov 2019 Planned End Date changed from 21 Aug 2025 to 28 Sep 2024.
- 19 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2019 Planned End Date changed from 18 Sep 2025 to 21 Aug 2025.